BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
Hyperprolactinemia might be related to weight gain, metabolic syndrome (MS), and insulin resistance (IR). Treatment with dopamine agonist (DA) has been shown to reduce body weight and improve metabolic parameters. The objectives of this study were to determine the prevalence of obesity, overweight, MS, and IR in patients with prolactinoma before and after therapy with DA and to evaluate the relation between prolactin (PRL), body weight, fat distribution, leptin levels, IR, and lipid profile before treatment. In addition, we investigated the correlation of the reduction in PRL levels with weight loss and metabolic profile improvement. Twenty-two patients with prolactinoma completed 6 months of treatment with DA. These patients were submitted to clinical (BMI, waist circumference, blood pressure (BP)), laboratory evaluation (leptin, glucose, low-density lipoprotein (LDL)-cholesterol, and triglyceride (TG) levels) and abdominal computed tomography (CT) before and after treatment. The statistical analyses were done by nonparametric tests. At the beginning of the study, the prevalence of obesity, overweight, MS, and IR was 45, 27, 27, and 18%, respectively. After 6 months of treatment with DA, PRL levels normalized, but no significant difference in BMI was observed. However, there was a significant decrease on homeostasis model assessment of insulin resistance (HOMA(IR)) index, glucose, LDL-cholesterol, and TG levels. This study suggests a possible involvement of prolactinoma on the prevalence of obesity. We should consider that DA may be effective on improving metabolic parameters, and we speculate that a period longer than 6 months of treatment is necessary to conclude whether this drug can interfere in the body weight of patients with prolactinoma.
dos Santos Silva
Cintia M
CM
Division of Endocrinology, Hospital Universitário Clementino Fraga Filho/Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Barbosa
Flavia R P
FR
Lima
Giovanna A B
GA
Warszawski
Leila
L
Fontes
Rosita
R
Domingues
Romeu C
RC
Gadelha
Mõnica R
MR
D000328:Adult; D000359:Aftercare; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D001823:Body Composition; D015992:Body Mass Index; D001835:Body Weight; D001971:Bromocriptine / Q000627:therapeutic use; D000077465:Cabergoline; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D020738:Leptin / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000453:epidemiology* / Q000209:etiology; D055442:Metabolome; D008875:Middle Aged; D009765:Obesity / Q000453:epidemiology* / Q000209:etiology; D015995:Prevalence; D015175:Prolactinoma / Q000188:drug therapy*; D055105:Waist Circumference; D015430:Weight Gain; D055815:Young Adult
D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D018491:Dopamine Agonists; D004873:Ergolines; D007328:Insulin; D020738:Leptin; D001971:Bromocriptine; D000077465:Cabergoline